Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

10.73 +0.39 (+3.82%)
Delayed Quote Updated: 2:49 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
News headline image
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
News headline image
How Is The Market Feeling About ADMA Biologics? ↗
 
Via Benzinga
News headline image
Expert Ratings For ADMA Biologics ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
News headline image
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist' ↗
Mad Money's Jim Cramer recommends holding on to Vertiv Holdings, which is set to report its Q2 results before the opening bell on July 24. 
Via Benzinga
News headline image
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biotech Arvinas Stock Earns 82 RS Rating ↗
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results ↗
 
Via Benzinga
News headline image
A Closer Look at 6 Analyst Recommendations For ADMA Biologics ↗
 
Via Benzinga
News headline image
3 Millionaire-Making Stock Picks With Astounding Growth Potential ↗
Owning millionaire-making stocks can be a life changer. Look no further than these three companies which are full of potential. 
Via InvestorPlace
News headline image
Bull Run Alert: 3 Stocks Set to Soar in the Coming Months ↗
Get ready for the next bull run with these stocks. All three are showing impressive growth and massive returns. 
Via InvestorPlace
News headline image
UroGen Pharma Stock Earns 91 RS Rating ↗
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
News headline image
Krystal Biotech Stock Sees RS Rating Jump To 91 ↗
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
News headline image
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024 ↗
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Chart Of The Day: ADMA Biologics - Hitting New Highs ↗
100% technical buy signals 8 new highs and up 7.24% in the last month 110.10+ Weighted Alpha 
Via Talk Markets
News headline image
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.